Iter-4360dd15-0005-transcript
第 5 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 rapamycin human trial systematic review PMC endpoints trial names primary endpoint"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0004-transcript", "tags": "iteration transcript", "modified": "20260424174235000", "preview": "!! 第 4 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin human trial systematic review endpoints safety\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0002-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424173549000\", \"preview\": \"!! 第 2 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 rapamycin senolytics NEXT_FOCUS human trial review\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_me → call list_recent({"n":8})
→ call list_by_tag({"limit":20,"tag":"4360dd15"})
→ call search_memory({"limit":8,"query":"4360dd15 PMC rapamycin review reference trials endpoints"})
→ call list_tools({})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0004-reflection", "modified": "20260424174242000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424174242000", "tags": "pinned focus"}, {"title": "先用可访问二级来源拼表", "modified": "20260424174242000", "tags": "lesson evidence retrieval human-trials"}, {"title": "Iter-4360dd15-0004-transcript", "modified": "20260424174235000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0004-critique-rapamycin-evidence", "modified": "20260424174226000", "tags": "lesson critique 4360dd15"}, {"title": "Iter-4360dd15-0003-reflection", "modified": "20260424173853000", "tags": "iteration reflection"}, {"title": "先用摘要锁定，再补全文校验", "modified": "20260424173853000", "tags": "lesson evidence human-trials retrieval"}, {"title": "Iter-4360dd15-0003-transcript", "modified": "20260424173843000", "tags": "iteration transcript"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "Iter-4360dd15-0004-critique-rapamycin-evidence", "modified": "20260424174226000"}, {"title": "Rapamycin human trials: extracted endpoints and outcomes from the 2024 systematic review review pass 1", "modified": "20260424173529000"}, {"title": "Human longevity interventions evidence maturity matrix 2026-04-25", "modified": "20260424173237000"}]}
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0004-transcript", "tags": "iteration transcript", "modified": "20260424174235000", "preview": "!! 第 4 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin human trial systematic review endpoints safety\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0002-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424173549000\", \"preview\": \"!! 第 2 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 rapamycin senolytics NEXT_FOCUS human trial review\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_me【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，//斜体//，[[其它tiddler]]。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio
→ call read_note({"title":"NEXT_FOCUS"})
→ call read_note({"title":"Rapamycin human trials: extracted endpoints and outcomes from the 2024 systematic review review pass 1"})
→ call read_note({"title":"Iter-4360dd15-0004-critique-rapamycin-evidence"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission `4360dd15` · Iter-0004）\n\n只攻克一件事：从 PMC 综述与其参考文献中逐项提取 rapamycin 人体试验名称及各自主要终点。"}
【tool:read_note】
{"ok": true, "title": "Rapamycin human trials: extracted endpoints and outcomes from the 2024 systematic review review pass 1", "tags": "knowledge fact experiment 4360dd15", "text": "!! Rapamycin human trial evidence from a 2024 systematic review\nThis round I narrowed the long-longevity question to a single mechanism: //rapamycin / mTOR//.\n\n!! Source\n[[Targeting ageing with rapamycin and its derivatives in humans: a systematic review]] (Lee, Hodzic Kuerec, Maier), //Lancet Healthy Longevity// 2024; 5(2):e152-e162. The VU repository page includes the abstract and full bibliographic metadata.\n\n!! Extracted human trial snapshot\nThe review reports: 18,400 unique records screened, 19 included studies. Benefits were seen mainly in immune, cardiovascular, and integumentary systems; no significant effects in endocrine, muscular, or neurological systems.\n\n| Study | Population | Agent | Dose / schedule | Design | Primary endpoint | Result |\n|---|---|---|---|---|---|---|\n| Krebs et al. 2007 | 11 men, 28 +/- 1 y | rapamycin | 6 mg single dose | randomized, double-blind, placebo-controlled, crossover | peripheral insulin sensitivity during insulin clamp + amino acid infusion | met |\n| Drummond et al. 2009 | 15 men, 29 +/- 2 y | rapamycin | 12 mg single dose 2 h before resistance exercise | acute exercise +/- rapamycin | post-exercise mixed-muscle protein synthesis | met |\n| Gunderman 2014 | 16 men, 26 +/- 1 y | rapamycin | 16 mg single dose 1 h before blood-flow-restricted re
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0004-critique-rapamycin-evidence", "tags": "lesson critique 4360dd15", "text": "!! Critique of the current rapamycin-human-evidence claim\n\nThis round I tested the weakest point in the current accumulation: the jump from \"a 2024 systematic review found 19 included studies\" to \"rapamycin is a mature anti-aging intervention in humans.\" That jump is too strong.\n\n!! What the public snippets actually support\n- PubMed metadata confirms the paper identity: [[Targeting ageing with rapamycin and its derivatives in humans: a systematic review.]] PMID 38310895.\n- Search snippets from The Lancet / ScienceDirect say the review found //19 included studies// after screening 18,400 unique records.\n- The accessible secondary review [[Blazing a trail for the clinical use of rapamycin as a geroprotecTOR]] provides a concrete human-trial table with only 8 completed studies, and they are //not homogeneous//:\n - 3 acute physiology studies in young men (insulin sensitivity / muscle protein synthesis)\n - 3 immune studies in older adults (everolimus / BEZ235 / rapamycin)\n - 1 topical skin study\n - 1 respiratory illness study (RTB101, not rapamycin)\n\n!! Why this is a likely failure point\nThe current narrative risks treating a heterogeneous set of mTOR-pathway interventions as if they were a single coherent rapamycin anti-aging signal. That is methodologically weak because:\n# the agents differ (rapamycin, everolimus, BEZ235, RTB101)\n# the popu
→ call web_search({"limit":5,"query":"PMC review rapamycin human trials geroprotector table primary endpoint rapamycin everolimus PMC"})
→ call web_search({"limit":5,"query":"Blazing a trail for the clinical use of rapamycin as a geroprotecTOR PMC table human trials"})
→ call pubmed_search({"limit":5,"query":"Targeting ageing with rapamycin and its derivatives in humans: a systematic review"})
→ call web_search({"limit":5,"query":"site:pmc.ncbi.nlm.nih.gov rapamycin human trial systematic review 19 studies PMC"})
【tool:web_search】
{"ok": true, "query": "PMC review rapamycin human trials geroprotector table primary endpoint rapamycin everolimus PMC", "results": [{"title": "Blazing a trail for the clinical use of rapamycin as a geroprotecTOR - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10643772/", "snippet": "It is important to note that this is not an endorsement for or against the use of mTOR inhibitors, but rather a compendium of upcoming clinical trials leveraging the last two decades of pre-clinical data to help advance our understanding of the impact of rapamycin on human healthspan."}, {"title": "Blazing a trail for the clinical use of rapamycin as a ... - Europe PMC", "url": "https://europepmc.org/article/pmc/10643772", "snippet": "The goal of this review is to (1) briefly showcase how mTORC1 inhibition by rapamycin and rapamycin analogs (rapalogs) can extend healthspan by maintaining, improving, or restoring select indices of physiological function in pre-clinical and some human studies ( Table (Table1);1); (2) discuss potential risks and key knowledge gaps regarding the ..."}, {"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00258-1/fulltext", "snippet": "Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological chang
【tool:web_search】
{"ok": true, "query": "Blazing a trail for the clinical use of rapamycin as a geroprotecTOR PMC table human trials", "results": [{"title": "Blazing a trail for the clinical use of rapamycin as a geroprotecTOR - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10643772/", "snippet": "It is important to note that this is not an endorsement for or against the use of mTOR inhibitors, but rather a compendium of upcoming clinical trials leveraging the last two decades of pre- clinical data to help advance our understanding of the impact of rapamycin on human healthspan."}, {"title": "Blazing a trail for the clinical use of rapamycin as a geroprotecTOR ...", "url": "https://europepmc.org/article/pmc/10643772", "snippet": "To address this need for additional information, a number of new clinical trials at the University of Wisconsin-Madison and around the world have begun or will begin in the near future to better study the effects of rapamycin and its analogs on age-related conditions ( Table (Table2).2)."}, {"title": "Blazing a trail for the clinical use of rapamycin as a geroprotecTOR", "url": "https://pubmed.ncbi.nlm.nih.gov/37801202/", "snippet": "Results from these early phase studies will help guide the design of phase 3 clinical trials to determine whether rapamycin can be used safely to inhibit mTORC1 for the treatment and prevention of age-related diseases in humans ."}, {"title": "Blazing a trail for the clinical use of rapamycin as a geroprotecTOR", "url": "https://
【tool:pubmed_search】
{"ok": true, "query": "Targeting ageing with rapamycin and its derivatives in humans: a systematic review", "results": [{"pmid": "38310895", "title": "Targeting ageing with rapamycin and its derivatives in humans: a systematic review.", "source": "Lancet Healthy Longev", "pubdate": "2024 Feb", "authors": ["Lee DJW", "Hodzic Kuerec A", "Maier AB"], "url": "https://pubmed.ncbi.nlm.nih.gov/38310895/"}, {"pmid": "28504837", "title": "Immunotherapy for metastatic renal cell carcinoma.", "source": "Cochrane Database Syst Rev", "pubdate": "2017 May 15", "authors": ["Unverzagt S", "Moldenhauer I", "Nothacker M", "Roßmeißl D", "Hadjinicolaou AV", "Peinemann F", "Greco F", "Seliger B"], "url": "https://pubmed.ncbi.nlm.nih.gov/28504837/"}]}
【tool:web_search】
{"ok": true, "query": "site:pmc.ncbi.nlm.nih.gov rapamycin human trial systematic review 19 studies PMC", "results": []}
→ call web_fetch({"max_chars":12000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10643772/"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10643772/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Blazing a trail for the clinical use of rapamycin as a geroprotecTOR - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice GeroScience . 2023 Oct 6;45(5):2769–2783. doi: 10.1007/s11357-023-00935-x Search in PMC Search in PubMed View in NLM Catalog Add to search Blazing a trail for the clinical use of rapamycin as a geroprotecTOR Adam R Konopka Adam R Konopka 1 Division of Geriatrics, Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705 USA 2 William S. Middlet
→ call run_python({"code":"from collections import Counter\nstudies = [\n {'study':'Krebs et al. 2007','agent':'rapamycin','endpoint':'increase in peripheral insulin sensitivity during insulin clamp + AA infusion','met':'yes'},\n {'study':'Drummond et al. 2009','agent':'rapamycin','endpoint':'difference in post-RE mixed-muscle protein synthesis rates','met':'yes'},\n {'study':'Gunderman 2014','agent':'rapa)
【tool:run_python】
{"ok": true, "stdout": "n_completed_in_table 8\nagent_counts Counter({'rapamycin': 4, 'everolimus': 1, 'everolimus/BEZ235': 1, 'topical rapamycin': 1, 'RTB101': 1})\nendpoint_counts Counter({'difference in post-RE mixed-muscle protein synthesis rates': 2, 'improvement in influenza vaccination response': 2, 'increase in peripheral insulin sensitivity during insulin clamp + AA infusion': 1, 'immunological response': 1, 'decreased p16-positive senescent cells in skin': 1, 'decrease in clinically symptomatic respiratory illness': 1})\ndirect_rapamycin_or_topical_count 5\nrapalog_or_other_mtor_count 3\n", "stderr": "", "returncode": 0}
→ call write_note({"tags":["knowledge","fact","4360dd15"],"text":"!! PMC review Table 1: completed human rapamycin / rapalog trials\n\nI re-read the accessible PMC review [[Blazing a trail for the clinical use of rapamycin as a geroprotecTOR]] (GeroScience 2023; PMCID PMC10643772) and extracted its completed-trial table.\n\n!! What this source actually contains\nThe table lists ''8 completed human studies'' and giv)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\Rapamycin_human_trials_completed_studies_table_from_PMC_review.tid", "title": "Rapamycin human trials: completed studies table from PMC review"}
【assistant】
我已把可访问的 PMC 二级综述里“已完成的人体 rapamycin / rapalog 研究表”重建出来了。
本轮窄任务完成情况：
- 锁定来源：**Blazing a trail for the clinical use of rapamycin as a geroprotecTOR**（PMCID PMC10643772）
- 提取到该表中的 **8 项已完成人体研究**
- 按 **agent / population / primary endpoint** 逐项整理
- 用代码核对：其中 **5 项直接使用 rapamycin（含 topical）**，**3 项是 rapalog/相关 mTOR 轴药物**
- 得到的关键结论是：这批人体证据是**碎片化的、终点高度异质**，不能直接概括成“rapamycin 已被证明能抗衰老”
我已把这份可引用表写入长期记忆：
- `Rapamycin human trials: completed studies table from PMC review`
下一轮最值得做的最窄子问题是：把 **2024 系统综述那 19 项纳入研究** 中、但 PMC 表里没出现的那些试验，按同样格式补齐并标出各自主要终点。
<NEXT_FOCUS>从 2024 系统综述的参考文献链中补出剩余的 19 项纳入研究，逐项标注 agent、population 和 primary endpoint。</NEXT_FOCUS>